Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,570 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).(INTerpath-004) | active not recruiting | Phase 2 | 272 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Jul 13, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer(REACH-EGFR) | recruiting | Phase 1 / Phase 2 | 315 | Voronoi, IncINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT02364557 | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival | completed | Phase 2 / Phase 3 | 129 | NRG OncologyOTHER | 4 | Jul 10, 2026 | clinicaltrials |
| NCT02481635 | A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 11 | University Health Network, TorontoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02635009 | Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 418 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT04037254 | Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring | completed | Phase 1 / Phase 2 | 22 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT04482309 | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors(DPT02) | active not recruiting | Phase 2 | 477 | AstraZenecaINDUSTRY | 17 | Jul 10, 2026 | clinicaltrials |
| NCT04824014 | 4FMFES-PET Imaging of ER+ Advanced Breast Cancers | recruiting | Phase 2 | 150 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07625930 | RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial(RESTAGE) | not yet recruiting | Phase 2 | 184 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05143957 | A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera | completed | Phase 2 | 50 | Ionis Pharmaceuticals, Inc.INDUSTRY | 5 | Jul 9, 2026 | clinicaltrials |
| NCT01387555 | A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib(TRAVERSE) | completed | Phase 2 | 129 | Jennerex BiotherapeuticsINDUSTRY | 7 | Jul 8, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05220098 | First-in-Human Study of TAK-280 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 69 | TakedaINDUSTRY | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT06927635 | Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer(SECURE) | recruiting | Phase 2 | 75 | University Health Network, TorontoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT01916785 | OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)(OPTIM-DASA) | completed | Phase 2 | 289 | Versailles HospitalOTHER | 2 | Jul 6, 2026 | clinicaltrials |
| NCT03331198 | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | active not recruiting | Phase 1 / Phase 2 | 320 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT03391479 | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05074355 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 244 | Karyopharm Therapeutics IncINDUSTRY | 19 | Jul 2, 2026 | clinicaltrials |
| NCT03330847 | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | active not recruiting | Phase 2 | 273 | AstraZenecaINDUSTRY | 15 | Jul 2, 2026 | clinicaltrials |
| NCT03391973 | Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)(CUP) | completed | Phase 2 | 33 | AHS Cancer Control AlbertaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03952585 | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | active not recruiting | Phase 2 / Phase 3 | 384 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT04895722 | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). | active not recruiting | Phase 2 | 302 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Jul 2, 2026 | clinicaltrials |
| NCT05785767 | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 / Phase 3 | 149 | Regeneron PharmaceuticalsINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.(ALACRITY) | recruiting | Phase 1 / Phase 2 | 91 | Alexion Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors(NAVIGATE) | completed | Phase 2 | 215 | BayerINDUSTRY | 25 | Jul 1, 2026 | clinicaltrials |
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy(COSTAR Lung) | active not recruiting | Phase 2 / Phase 3 | 758 | GlaxoSmithKlineINDUSTRY | 24 | Jul 1, 2026 | clinicaltrials |
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)(LIBRA) | recruiting | Phase 2 | 278 | AstraZenecaINDUSTRY | 12 | Jul 1, 2026 | clinicaltrials |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT03600883 | A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | completed | Phase 1 / Phase 2 | 713 | AmgenINDUSTRY | 16 | Jun 30, 2026 | clinicaltrials |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 336 | Forma Therapeutics, Inc.INDUSTRY | 9 | Jun 29, 2026 | clinicaltrials |
| NCT06191250 | --SuPERIOR Trial-- | terminated | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07528417 | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)(MYELO-CAN:ABX) | not yet recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02581137 | Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2026 | clinicaltrials |
| NCT04614103 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | recruiting | Phase 2 | 170 | Iovance Biotherapeutics, Inc.INDUSTRY | 12 | Jun 26, 2026 | clinicaltrials |
| NCT04619069 | Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | suspended | Phase 2 / Phase 3 | 1,714 | NRG OncologyOTHER | 5 | Jun 25, 2026 | clinicaltrials |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217119 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217184 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 11 | Jun 25, 2026 | clinicaltrials |
| NCT01657331 | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)(SGN+Benda) | completed | Phase 1 / Phase 2 | 65 | Columbia UniversityOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT02553460 | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | active not recruiting | Phase 1 / Phase 2 | 50 | St. Jude Children's Research HospitalOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | recruiting | Phase 2 | 37 | GlaxoSmithKlineINDUSTRY | 8 | Jun 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials